BioCentury | Dec 15, 2017
Company News

Allergan to acquire Repros

...Allergan plc (NYSE:AGN) is acquiring Repros Therapeutics Inc. (NASDAQ:RPRX) for $0.67 per share in cash. Repros said it...
...modulator (SPRM) under FDA review to treat abnormal uterine bleeding in women with uterine fibroids. Repros'...
...Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Allergan plc (NYSE:AGN), Dublin, Ireland Business: Endocrine/Metabolic, Genitourinary Jennie Walters enclomiphene citrate Proellex Proellex-V Allergan Inc. Repros Therapeutics Inc. Androgen...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:ARGX) 5/18/17 $114.7 $456.8 $569.9 25% Halozyme Therapeutics Inc. (NASDAQ:HALO) 5/18/17 $143.8 $1,766.8 $1,811.7 3% Repros Therapeutics Inc....
BioCentury | Apr 13, 2017
Clinical News

Proellex telapristone acetate: Clinical hold ongoing

...The agency subsequently converted the full hold to a partial hold in 2010 to allow Repros...
...conduct a Phase II trial of ≤12 mg Proellex, and again in 2012 to allow Repros...
...of low-dose Proellex (see BioCentury, Aug. 10, 2009 & Oct. 15, 2012 ). Last November, Repros...
BioCentury | Oct 10, 2016
Clinical News

Enclomiphene citrate regulatory update

...EMA accepted for review an MAA from Repros for enclomiphene to treat secondary hypogonadism. Last year...
...function. The agency recommended Repros conduct >=1 Phase III trial (see BioCentury, Dec. 7, 2015). Repros Therapeutics Inc....
BioCentury | Sep 26, 2016
Clinical News

Proellex telapristone: Phase II data

...Repros said 70% of patients treated with Proellex became amenorrheic. Proellex was generally well tolerated. Repros Therapeutics Inc....
BioCentury | Sep 19, 2016
Clinical News

Enclomiphene citrate regulatory update

...recommended Repros conduct 1 or more additional Phase III trials (see BioCentury, Dec. 7, 2015). Repros Therapeutics Inc....
BioCentury | Sep 5, 2016
Clinical News

Enclomiphene citrate: Interim Phase II data

...recommended Repros conduct 1 or more additional Phase III trials (see BioCentury, Dec. 7, 2015). Repros Therapeutics Inc....
BioCentury | Apr 25, 2016
Clinical News

Telapristone: Phase IIb data

...a second 18-week course of treatment separated by an off-drug interval to allow for menses. Repros...
...evaluating an oral formulation of Proellex in a Phase IIb trial to treat uterine fibroids. Repros Therapeutics Inc....
BioCentury | Feb 22, 2016
Clinical News

Enclomiphene citrate: Completed Phase II enrollment

...in combination with diet and exercise. Last year, FDA issued a complete response letter to Repros...
...recommended Repros conduct 1 or more additional Phase III trials (see BioCentury, Dec. 7, 2015). Repros Therapeutics Inc....
BioCentury | Jan 18, 2016
Company News

Repros endocrine/metabolic news

...a co-inventor of U.S. Patent Nos. 7,737,185 and 7,759,360, which cover enclomiphene. Dr. Fisch sent Repros...
...the patents as well as U.S. Patent No. 7,173,064, also covering enclomiphene. In August 2013, Repros...
...CAFC (see BioCentury, Aug. 19, 2013). Last year, FDA issued a complete response letter to Repros...
Items per page:
1 - 10 of 339
BioCentury | Dec 15, 2017
Company News

Allergan to acquire Repros

...Allergan plc (NYSE:AGN) is acquiring Repros Therapeutics Inc. (NASDAQ:RPRX) for $0.67 per share in cash. Repros said it...
...modulator (SPRM) under FDA review to treat abnormal uterine bleeding in women with uterine fibroids. Repros'...
...Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Allergan plc (NYSE:AGN), Dublin, Ireland Business: Endocrine/Metabolic, Genitourinary Jennie Walters enclomiphene citrate Proellex Proellex-V Allergan Inc. Repros Therapeutics Inc. Androgen...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:ARGX) 5/18/17 $114.7 $456.8 $569.9 25% Halozyme Therapeutics Inc. (NASDAQ:HALO) 5/18/17 $143.8 $1,766.8 $1,811.7 3% Repros Therapeutics Inc....
BioCentury | Apr 13, 2017
Clinical News

Proellex telapristone acetate: Clinical hold ongoing

...The agency subsequently converted the full hold to a partial hold in 2010 to allow Repros...
...conduct a Phase II trial of ≤12 mg Proellex, and again in 2012 to allow Repros...
...of low-dose Proellex (see BioCentury, Aug. 10, 2009 & Oct. 15, 2012 ). Last November, Repros...
BioCentury | Oct 10, 2016
Clinical News

Enclomiphene citrate regulatory update

...EMA accepted for review an MAA from Repros for enclomiphene to treat secondary hypogonadism. Last year...
...function. The agency recommended Repros conduct >=1 Phase III trial (see BioCentury, Dec. 7, 2015). Repros Therapeutics Inc....
BioCentury | Sep 26, 2016
Clinical News

Proellex telapristone: Phase II data

...Repros said 70% of patients treated with Proellex became amenorrheic. Proellex was generally well tolerated. Repros Therapeutics Inc....
BioCentury | Sep 19, 2016
Clinical News

Enclomiphene citrate regulatory update

...recommended Repros conduct 1 or more additional Phase III trials (see BioCentury, Dec. 7, 2015). Repros Therapeutics Inc....
BioCentury | Sep 5, 2016
Clinical News

Enclomiphene citrate: Interim Phase II data

...recommended Repros conduct 1 or more additional Phase III trials (see BioCentury, Dec. 7, 2015). Repros Therapeutics Inc....
BioCentury | Apr 25, 2016
Clinical News

Telapristone: Phase IIb data

...a second 18-week course of treatment separated by an off-drug interval to allow for menses. Repros...
...evaluating an oral formulation of Proellex in a Phase IIb trial to treat uterine fibroids. Repros Therapeutics Inc....
BioCentury | Feb 22, 2016
Clinical News

Enclomiphene citrate: Completed Phase II enrollment

...in combination with diet and exercise. Last year, FDA issued a complete response letter to Repros...
...recommended Repros conduct 1 or more additional Phase III trials (see BioCentury, Dec. 7, 2015). Repros Therapeutics Inc....
BioCentury | Jan 18, 2016
Company News

Repros endocrine/metabolic news

...a co-inventor of U.S. Patent Nos. 7,737,185 and 7,759,360, which cover enclomiphene. Dr. Fisch sent Repros...
...the patents as well as U.S. Patent No. 7,173,064, also covering enclomiphene. In August 2013, Repros...
...CAFC (see BioCentury, Aug. 19, 2013). Last year, FDA issued a complete response letter to Repros...
Items per page:
1 - 10 of 339